BioCentury | Feb 8, 2018
Finance

External rethink

...have their own advantages because accessing an innovative asset is often inexpensive, and “there’s a galaxy...
BioCentury | Jul 11, 2016
Financial News

Aslan completes venture financing

...TopTaiwan; KGI VC; Ta Ya Venture Capital; Milestone Capital; Daiwa Corporate Investment Co. Ltd.; China Galaxy...
BioCentury | Jul 6, 2016
Financial News

Aslan raises $23M in pre-IPO round

...included TopTaiwan, KGI VC, Ta Ya Ventures, Milestone Capital, Daiwa Taiwan-Japan Biotech Fund and China Galaxy...
BioCentury | Apr 11, 2016
Company News

Interpace Diagnostics, Galaxy Health sales and marketing update

...Interpace said Galaxy Health Network will cover all of Interpace’s molecular pathology tests and services. Interpace’s...
...Galaxy Health covers more than 3.5 million lives. Interpace Diagnostics Group Inc. (NASDAQ:IDXG), Parsippany, N.J. Galaxy...
BioCentury | Jan 4, 2016
Finance

Big band swing

...notes that FDA requires 12-month stability data Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Terminates the Phase III GALAXY-2...
BioCentury | Oct 26, 2015
Strategy

Collaborating on combos

...Pharma Pvt. Ltd. CRD1152 Indoleamine 2,3-dioxygenase (INDO; IDO); tryptophan 2,3-dioxygenase (TDO2; TDO) Preclin Not started Galaxy Biotech LLC...
BioCentury | Oct 26, 2015
Analyst Picks & Changes

Analyst picks & changes

...Partners Joe Pantginis Downgrade Neutral (from buy) Peaker downgraded after Synta terminated the Phase III GALAXY-2...
BioCentury | Oct 26, 2015
Clinical News

Ganetespib: Phase III discontinued

...Synta discontinued the open-label, international Phase III GALAXY-2 trial in about 850 patients with stage IIIB/IV...
BioCentury | Oct 22, 2015
Clinical News

Synta halting ganetespib study after futility analysis

...NASDAQ:SNTA) sank $1.30 (64%) to $0.74 after it said it will terminate the Phase III GALAXY-2...
...data from the studies next year. Synta said there were no new safety signals in GALAXY-2...
BioCentury | Aug 11, 2014
Clinical News

Ganetespib: Phase II/III ongoing

...to start this year (see BioCentury, March 17). Ganetespib also is in the Phase III GALAXY-2...
Items per page:
1 - 10 of 62
BioCentury | Feb 8, 2018
Finance

External rethink

...have their own advantages because accessing an innovative asset is often inexpensive, and “there’s a galaxy...
BioCentury | Jul 11, 2016
Financial News

Aslan completes venture financing

...TopTaiwan; KGI VC; Ta Ya Venture Capital; Milestone Capital; Daiwa Corporate Investment Co. Ltd.; China Galaxy...
BioCentury | Jul 6, 2016
Financial News

Aslan raises $23M in pre-IPO round

...included TopTaiwan, KGI VC, Ta Ya Ventures, Milestone Capital, Daiwa Taiwan-Japan Biotech Fund and China Galaxy...
BioCentury | Apr 11, 2016
Company News

Interpace Diagnostics, Galaxy Health sales and marketing update

...Interpace said Galaxy Health Network will cover all of Interpace’s molecular pathology tests and services. Interpace’s...
...Galaxy Health covers more than 3.5 million lives. Interpace Diagnostics Group Inc. (NASDAQ:IDXG), Parsippany, N.J. Galaxy...
BioCentury | Jan 4, 2016
Finance

Big band swing

...notes that FDA requires 12-month stability data Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Terminates the Phase III GALAXY-2...
BioCentury | Oct 26, 2015
Strategy

Collaborating on combos

...Pharma Pvt. Ltd. CRD1152 Indoleamine 2,3-dioxygenase (INDO; IDO); tryptophan 2,3-dioxygenase (TDO2; TDO) Preclin Not started Galaxy Biotech LLC...
BioCentury | Oct 26, 2015
Analyst Picks & Changes

Analyst picks & changes

...Partners Joe Pantginis Downgrade Neutral (from buy) Peaker downgraded after Synta terminated the Phase III GALAXY-2...
BioCentury | Oct 26, 2015
Clinical News

Ganetespib: Phase III discontinued

...Synta discontinued the open-label, international Phase III GALAXY-2 trial in about 850 patients with stage IIIB/IV...
BioCentury | Oct 22, 2015
Clinical News

Synta halting ganetespib study after futility analysis

...NASDAQ:SNTA) sank $1.30 (64%) to $0.74 after it said it will terminate the Phase III GALAXY-2...
...data from the studies next year. Synta said there were no new safety signals in GALAXY-2...
BioCentury | Aug 11, 2014
Clinical News

Ganetespib: Phase II/III ongoing

...to start this year (see BioCentury, March 17). Ganetespib also is in the Phase III GALAXY-2...
Items per page:
1 - 10 of 62